Overall, this is a well-designed scientifically credible protocol, which should meet it aims of answering unanswered questions regarding the risk of occult cancer in patients with unprovoked VTE, as well as the extent and potential benefits of screening depending on patient"s perceived risk.
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GENERAL COMMENTS
Van Es et al describe the protocol for a systematic review and individual patient data meta-analysis on screening for occult cancer in patients with unprovoked venous thromboembolism. This is a relevant topic for clinicians dealing with venous thromboembolism.
Major problems: Methods: the authors describe the protocol for the individual patients meta-analysis, and this would imply that only methods for study selection and data pooling would be presented along with the planned statistical analysis. The systematic review has already been registered in the PROSPERO registry. However the authors report on included (10 studies) and excluded studies and on those studies which will provide the individual data. A full paper with completed results would be more intersesting and the reasons for presenting the protocol separately from the full paper are unclear.
Research question n.3: existing risk prediction scores or models for cancer in patients with unprovoked venous thromboembolism should be briefly described. Moreover 20 different variables will be considered for building a prediction model, however only 156 patients developed cancer at follow-up among 3034 patients enrolled in the 10 included studies. Overfitting should be avoided (eg introducing only those variables significant after univariate analysis). It should be specified whether the index DVT was proximal or distal
Research question n.6: it should be specified which "various" imaging tests will be considered, e.g. only CT abdomen and whole body PET/CT or also other imaging modalities such as ultrasound.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 1. …in terms of individual study quality, I note that the criteria for unprovoked venous thromboembolism was defined as "symptomatic lower extremity DVT or PE in the absence of major provoking factors, such as recent surgery or immobilization, known cancer, and pregnancy". This excludes other recognized risk factors for provoked venous thromboembolism such as hospital admission, oestrogen therapy, obesity and known thrombophilia, among others. Therefore adapting the term "unprovoked VTE" could be inappropriate for some of the cases of VTE, which may have occurred in the presence of a recognized provoking factor.
Response: We thank the reviewer for bringing up this important issue. Eligible studies had to enrol patients without major provoking factors according to the ISTH recommendations (Kearon et al., JTH, 2016 ), but studies that enrolled patients with minor provoking factors (e.g. estrogen therapy or longhaul travel) were not excluded. Yet, the definitions of unprovoked VTE appeared to be quite homogeneous across the studies; patients with recent hospital admissions or known thrombophilia were excluded in most studies. A subgroup analysis for estrogen therapy is planned.
The definition of an unprovoked VTE varied somewhat across the studies. However, we expect that information on many minor provoking factors (e.g. obesity) will not be available in the studies. Therefore, we will therefore accept the definitions of unprovoked VTE used in the studies and will not be able to fully homogenize the patient populations.
We have now more clearly acknowledged this limitation of the present IPDMA in the "Limitations and challenges" section:
"Pooling of data may be biased due to differences across the studies with respect to inclusion criteria, time from VTE to enrolment, and definitions of baseline and outcome variables. For example, patients with minor provoking factors (e.g. estrogen therapy and long-haul travel) were included in some studies, while others excluded those patients."
Reviewer 2 1) Methods: the authors describe the protocol for the individual patients meta-analysis, and this would imply that only methods for study selection and data pooling would be presented along with the planned statistical analysis. The systematic review has already been registered in the PROSPERO registry. However the authors report on included (10 studies) and excluded studies and on those studies which will provide the individual data. A full paper with completed results would be more interesting and the reasons for presenting the protocol separately from the full paper are unclear.
Response: e completely agree with the reviewer that a full paper with completed results will be very interesting. As the reviewer mentioned, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (The PRISMA Statement) recommends having a systematic review registered on a public registration website (e.g. PROSPERO). It also suggests having the protocol widely available (Item 4 of PRISMA checklist) and published in order to ensure that the systematic review is well conducted. The aim of this publication is to have the protocol peered-reviewed and available on-line as recommended by the PRISMA Statement.
2) Research question n.3: existing risk prediction scores or models for cancer in patients with unprovoked venous thromboembolism should be briefly described. Moreover 20 different variables will be considered for building a prediction model, however only 156 patients developed cancer at follow-up among 3034 patients enrolled in the 10 included studies. Over-fitting should be avoided (e.g. introducing only those variables significant after univariate analysis). It should be specified whether the index DVT was proximal or distal.
Responses: We completely agree with the reviewer and added two references to include existing prediction scores for cancer detection in patients with VTE (See references below).
We completely agree that overfitting should be avoided. The coefficients will therefore be shrunk following bootstrapping procedures to account for optimism in the model. To avoid inappropriate selection of variables due to a low number of events per variable in the initial model, we will include only those variables associated with cancer at P<0.50.
Finally, we have specified that DVT could be either distal or proximal (page 6). 3) Research question n.6: it should be specified which "various" imaging tests will be considered, e.g. only CT abdomen and whole body PET/CT or also other imaging modalities such as ultrasound.
We thank the reviewer for highlighting this issue. In order to specify which imaging test will be analyzed, we edited the document to read: "What is the diagnostic accuracy of the various diagnostic components of an extensive screening strategy (CT Chest, CT abdomen, US abdomen and wholebody PET/CT?"
In summary, we again thank the editor and reviewers for their helpful comments and suggestions which have strengthened our manuscript. We thank you for considering our revised manuscript for publication in your journal and look forward to hearing from you. 
GENERAL COMMENTS
Recent research has consistently suggested that extensive screening for cancer in patients presenting with an unprovoked venous thromboembolism is not warranted. This protocol aims to advise more accurately on the utility of screening, the extent of limited screening for cancer which should be employed, personalising this with regards to individual patient risk.
The introduction sets the scene well and outlines areas of interest, namely, identification of risk factors for occult cancer and thus highrisk patients for whom the limited screen might need to be enhanced, the impact of occult cancer screening on cancer-related mortality and the outcome of patients with a negative limited screen.
In the eligibility criteria, it seems reasonable to exclude studies before 2000, for the reasons stated. The risk of influence from bias and confounding factors has been addressed in several ways, including the choice of inclusion of only randomized controlled trials and prospective cohort studies. The risk of bias from individual studies has also been addressed. However, in terms of individual study quality, I note that the criteria for unprovoked venous thromboembolism was defined as "symptomatic lower extremity DVT or PE in the absence of major provoking factors, such as recent surgery or immobilization, known cancer, and pregnancy". This excludes other recognized risk factors for provoked venous thromboembolism such as hospital admission, oestrogen therapy, obesity and known thrombophilia, among others. Therefore adapting the term "unprovoked VTE" could be inappropriate for some of the cases of VTE, which may have occurred in the presence of a recognized provoking factor. However, as there is not a 'universal list' of provoking factors for VTE which can be used as a standard, it might be difficult to exclude studies which have not included an exhaustive list. The research questions are relevant and clearly stated. The data analysis methods have been discussed in a detailed manner, and limitations clearly outlined. Overall, this is a well-designed scientifically credible protocol, which should meet it aims of answering unanswered questions regarding the risk of occult cancer in patients with unprovoked VTE, as well as the extent and potential benefits of screening depending on patient"s perceived risk.
